Annual EBITDA
-$7.29 M
+$431.80 K+5.59%
31 December 2023
Summary:
Evoke Pharma annual earnings before interest, taxes, depreciation & amortization is currently -$7.29 million, with the most recent change of +$431.80 thousand (+5.59%) on 31 December 2023. During the last 3 years, it has risen by +$5.75 million (+44.08%). EVOK annual EBITDA is now -265.80% below its all-time high of -$1.99 million, reached on 31 December 2012.EVOK EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$1.19 M
-$43.80 K-3.83%
30 September 2024
Summary:
Evoke Pharma quarterly earnings before interest, taxes, depreciation & amortization is currently -$1.19 million, with the most recent change of -$43.80 thousand (-3.83%) on 30 September 2024. Over the past year, it has increased by +$381.50 thousand (+24.33%). EVOK quarterly EBITDA is now -494.39% below its all-time high of -$199.60 thousand, reached on 30 June 2013.EVOK Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$5.65 M
+$381.50 K+6.33%
30 September 2024
Summary:
Evoke Pharma TTM earnings before interest, taxes, depreciation & amortization is currently -$5.65 million, with the most recent change of +$381.50 thousand (+6.33%) on 30 September 2024. Over the past year, it has increased by +$1.46 million (+20.58%). EVOK TTM EBITDA is now -1028.67% below its all-time high of -$500.20 thousand, reached on 31 March 2012.EVOK TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EVOK EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +5.6% | +24.3% | +20.6% |
| 3 y3 years | +44.1% | +35.6% | +35.1% |
| 5 y5 years | +9.0% | +27.1% | +24.5% |
EVOK EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +44.1% | -3.8% | +44.0% | at high | +35.1% |
| 5 y | 5 years | -2.3% | +44.1% | -3.8% | +83.0% | at high | +58.9% |
| alltime | all time | -265.8% | +44.5% | -494.4% | +83.0% | -1028.7% | +58.9% |
Evoke Pharma EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$1.19 M(+3.8%) | -$5.65 M(-6.3%) |
| June 2024 | - | -$1.14 M(-21.5%) | -$6.03 M(-9.1%) |
| Mar 2024 | - | -$1.46 M(-21.8%) | -$6.63 M(-9.1%) |
| Dec 2023 | -$7.29 M(-5.6%) | -$1.86 M(+18.7%) | -$7.29 M(+2.6%) |
| Sept 2023 | - | -$1.57 M(-10.1%) | -$7.11 M(-4.3%) |
| June 2023 | - | -$1.74 M(-17.8%) | -$7.43 M(-4.7%) |
| Mar 2023 | - | -$2.12 M(+26.4%) | -$7.79 M(+0.9%) |
| Dec 2022 | -$7.72 M(-3.9%) | -$1.68 M(-11.2%) | -$7.72 M(+1.7%) |
| Sept 2022 | - | -$1.89 M(-10.5%) | -$7.59 M(+0.6%) |
| June 2022 | - | -$2.11 M(+2.8%) | -$7.55 M(-0.8%) |
| Mar 2022 | - | -$2.05 M(+32.6%) | -$7.61 M(-5.4%) |
| Dec 2021 | -$8.04 M(-38.4%) | -$1.55 M(-16.1%) | -$8.04 M(-7.6%) |
| Sept 2021 | - | -$1.84 M(-14.9%) | -$8.70 M(-2.6%) |
| June 2021 | - | -$2.17 M(-12.7%) | -$8.94 M(-34.9%) |
| Mar 2021 | - | -$2.48 M(+12.4%) | -$13.73 M(+5.3%) |
| Dec 2020 | -$13.04 M(+83.0%) | -$2.21 M(+6.2%) | -$13.04 M(+6.4%) |
| Sept 2020 | - | -$2.08 M(-70.2%) | -$12.25 M(+3.8%) |
| June 2020 | - | -$6.96 M(+289.0%) | -$11.80 M(+69.8%) |
| Mar 2020 | - | -$1.79 M(+26.2%) | -$6.95 M(-2.5%) |
| Dec 2019 | -$7.13 M(-11.1%) | -$1.42 M(-12.9%) | -$7.13 M(-4.7%) |
| Sept 2019 | - | -$1.63 M(-23.0%) | -$7.48 M(+1.4%) |
| June 2019 | - | -$2.11 M(+7.3%) | -$7.38 M(-2.5%) |
| Mar 2019 | - | -$1.97 M(+11.4%) | -$7.57 M(-5.6%) |
| Dec 2018 | -$8.01 M | -$1.77 M(+16.1%) | -$8.01 M(-10.0%) |
| Sept 2018 | - | -$1.52 M(-34.0%) | -$8.91 M(-19.7%) |
| June 2018 | - | -$2.31 M(-4.6%) | -$11.08 M(-5.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | -$2.42 M(-9.1%) | -$11.67 M(+3.9%) |
| Dec 2017 | -$11.23 M(+6.5%) | -$2.66 M(-28.2%) | -$11.23 M(+3.1%) |
| Sept 2017 | - | -$3.70 M(+28.1%) | -$10.90 M(+16.4%) |
| June 2017 | - | -$2.89 M(+45.9%) | -$9.36 M(-0.1%) |
| Mar 2017 | - | -$1.98 M(-14.8%) | -$9.37 M(-11.1%) |
| Dec 2016 | -$10.54 M(-10.8%) | -$2.32 M(+7.1%) | -$10.54 M(-2.1%) |
| Sept 2016 | - | -$2.17 M(-25.1%) | -$10.77 M(-4.3%) |
| June 2016 | - | -$2.90 M(-8.1%) | -$11.26 M(-2.3%) |
| Mar 2016 | - | -$3.15 M(+23.6%) | -$11.53 M(-2.5%) |
| Dec 2015 | -$11.82 M(-10.1%) | -$2.55 M(-4.0%) | -$11.82 M(-3.1%) |
| Sept 2015 | - | -$2.66 M(-16.0%) | -$12.19 M(-8.7%) |
| June 2015 | - | -$3.16 M(-8.1%) | -$13.35 M(-2.4%) |
| Mar 2015 | - | -$3.45 M(+17.8%) | -$13.68 M(+4.0%) |
| Dec 2014 | -$13.15 M(+391.3%) | -$2.92 M(-23.5%) | -$13.15 M(+11.4%) |
| Sept 2014 | - | -$3.82 M(+9.5%) | -$11.80 M(+40.0%) |
| June 2014 | - | -$3.49 M(+19.5%) | -$8.43 M(+64.0%) |
| Mar 2014 | - | -$2.92 M(+85.1%) | -$5.14 M(+92.0%) |
| Dec 2013 | -$2.68 M(+34.3%) | -$1.58 M(+253.5%) | -$2.68 M(+52.7%) |
| Sept 2013 | - | -$446.00 K(+123.4%) | -$1.75 M(-1.8%) |
| June 2013 | - | -$199.60 K(-56.1%) | -$1.78 M(-8.2%) |
| Mar 2013 | - | -$454.70 K(-30.4%) | -$1.94 M(-2.3%) |
| Dec 2012 | -$1.99 M(-16.9%) | -$653.00 K(+36.7%) | -$1.99 M(+48.9%) |
| Sept 2012 | - | -$477.70 K(+33.2%) | -$1.34 M(+55.6%) |
| June 2012 | - | -$358.70 K(-28.3%) | -$858.90 K(+71.7%) |
| Mar 2012 | - | -$500.20 K | -$500.20 K |
| Dec 2011 | -$2.40 M | - | - |
FAQ
- What is Evoke Pharma annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Evoke Pharma?
- What is Evoke Pharma annual EBITDA year-on-year change?
- What is Evoke Pharma quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Evoke Pharma?
- What is Evoke Pharma quarterly EBITDA year-on-year change?
- What is Evoke Pharma TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Evoke Pharma?
- What is Evoke Pharma TTM EBITDA year-on-year change?
What is Evoke Pharma annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of EVOK is -$7.29 M
What is the all time high annual EBITDA for Evoke Pharma?
Evoke Pharma all-time high annual earnings before interest, taxes, depreciation & amortization is -$1.99 M
What is Evoke Pharma annual EBITDA year-on-year change?
Over the past year, EVOK annual earnings before interest, taxes, depreciation & amortization has changed by +$431.80 K (+5.59%)
What is Evoke Pharma quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of EVOK is -$1.19 M
What is the all time high quarterly EBITDA for Evoke Pharma?
Evoke Pharma all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$199.60 K
What is Evoke Pharma quarterly EBITDA year-on-year change?
Over the past year, EVOK quarterly earnings before interest, taxes, depreciation & amortization has changed by +$381.50 K (+24.33%)
What is Evoke Pharma TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of EVOK is -$5.65 M
What is the all time high TTM EBITDA for Evoke Pharma?
Evoke Pharma all-time high TTM earnings before interest, taxes, depreciation & amortization is -$500.20 K
What is Evoke Pharma TTM EBITDA year-on-year change?
Over the past year, EVOK TTM earnings before interest, taxes, depreciation & amortization has changed by +$1.46 M (+20.58%)